Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-06-14
2005-06-14
McKenzie, Thomas (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S379000
Reexamination Certificate
active
06906072
ABSTRACT:
The present invention provides a novel compound having a superior calcium antagonism, in particular, a neuron-selective calcium antagonism. Namely, it provides a compound represented by the following formula, a salt thereof or a hydrate of them.In the formula, Ar indicates an optionally substituted 5- to 14-membered aromatic ring etc.; the ring A indicates any one ring selected from a piperazine, a homopiperazine, a piperidine and the like; the ring B indicates an optionally substituted C3-14on hydrocarbon ring etc.; E indicates a single bond, a group represented by the formula —CO—, etc.; X indicates a single bond, an oxygen atom etc.; R1indicates a hydrogen atom, a halogen atom, a hydroxyl group etc.; and D1, D2, W1and W2are the same as or different from each other and each represents a single bond or an optionally substituted C1-6alkylene chain.
REFERENCES:
patent: 4994460 (1991-02-01), Dextraze et al.
patent: 5231105 (1993-07-01), Shoji
patent: 5281601 (1994-01-01), Cross
patent: 5420131 (1995-05-01), Carceller et al.
patent: 6117875 (2000-09-01), Shimazaki et al.
patent: 6426345 (2002-07-01), Shimazaki et al.
patent: 0 393 574 (1990-10-01), None
patent: 393574 (1990-10-01), None
patent: 400661 (1990-12-01), None
patent: 0 400 661 (1990-12-01), None
patent: 0 441 226 (1991-08-01), None
patent: 441226 (1991-08-01), None
patent: 0 458 459 (1991-11-01), None
patent: 458459 (1991-11-01), None
patent: 2676225 (1992-11-01), None
patent: 2676225 (1992-11-01), None
patent: 1305458 (1973-01-01), None
patent: 1305458 (1973-01-01), None
patent: 47-38984 (1972-12-01), None
patent: 47-38984 (1972-12-01), None
patent: 62-286980 (1987-12-01), None
patent: 62-286980 (1987-12-01), None
patent: 62-286980 (1987-12-01), None
patent: 63-35562 (1988-02-01), None
patent: 63-35562 (1988-02-01), None
patent: 64-3182 (1989-01-01), None
patent: 64-3182 (1989-01-01), None
patent: 64-61468 (1989-03-01), None
patent: 64-61468 (1989-03-01), None
patent: 2-83375 (1990-03-01), None
patent: 2-83375 (1990-03-01), None
patent: 5-97673 (1993-04-01), None
patent: 5-97673 (1993-04-01), None
patent: 11-80155 (1999-03-01), None
patent: 11-80155 (1999-03-01), None
patent: 91/09015 (1991-06-01), None
patent: WO 91/09015 (1991-06-01), None
patent: 441226 (1991-08-01), None
patent: WO 91/18899 (1991-12-01), None
patent: 91/18899 (1991-12-01), None
patent: 96/26196 (1996-08-01), None
patent: WO 96/26196 (1996-08-01), None
patent: 97/26258 (1997-07-01), None
patent: WO 97/26258 (1997-07-01), None
patent: WO 99/06383 (1999-02-01), None
patent: 99/06383 (1999-02-01), None
patent: WO 00/05210 (2000-02-01), None
patent: 00/05210 (2000-02-01), None
Jain KK., Expert Opin Investig Drugs. Oct. 2000;9(10):2403-10, Medline abstract PMID: 11060815.
Gilmore, J. et al, Ann. Report Med. Chem., vol. 30, 1995, p 51-60.
Moehrle et al., Arch. Pharm., vol. 326(6), pp. 565-568, Compound No. 4 (1995).
Butora et al., Collect. ,Czech. Chem. Comm., Compound vol. 57 (9), pp. 1967-1981, No. 7 (1992).
Carceller et al., J. Med. Chem., vol. 35(22), pp. 4118-4134 (1992).
Laguere et al., Eur. J. Med., vol. 25(4), pp. 351-359, (1990).
Vartanyan et al., Khim.-Farm. Zh., vol. 23(5), pp. 562-565, Compound. No. 7 (1989).
Lachowicz et al., Life Sci., vol. 64(6/7), pp. 535-539 (1999).
Yevich et al., J. Med. Chem., vol. 35(24), pp. 4516-4525, No. 4,31 (1992).
Butora et al., Collect. Czech. Chem. Comm., vol. 57, No. 9, pp. 1967-1981, (1992).
Carceller et al., J. Med. Chem., vol. 35, No. 22, pp. 4118-4134, (1992).
Laguerre et al., Eur. J. Med. Chem., vol. 25, No. 4, pp. 351-359, (1990).
Vartanyan et al., Khim. -Farm. Zh., vol. 23, No. 5, pp. 562-565, (1989).
Lachowicz et al., Life Sci., vol. 64, No. 6/7, pp. 535-539, (1999).
Yevich et al., J. Med. Chem., vol. 35, No. 24, pp. 4516-4525, (1992).
Laurie et al., Naunyn-Schmiedeberg's Arch. Pharmacol., vol. 351, No. 6, pp. 565-568, (1995).
Tani, M., Annu. Rev. Physiol., vol. 52, pp. 543-559, (1990).
Scrip, No. 2203, vol. 24, (1997).
Lipton, S., Advances in Pharmacology, vol. 22, pp. 271-297, (1991).
Mattson et al., TINS, vol. 16, No. 10, pp. 409-414, (1993).
Nichiyakurishi, Folia. Pharmacol. Japon., vol. 86, pp. 323-328, (1985).
Drugs of the Future, vol. 23, No. 2, pp. 152-160, (1998).
Dobrovsky et al., Casopis Lekaru Ceskych, vol. 130, No. 22-23, pp. 625-630, (1991).
Jimenes-Jimenez et al., Rev. Neurol., vol. 24, No. 134, pp. 1199-1209, (1996).
Asakura et al., Brain Research, vol. 776, pp. 140-145, (1997).
Jyunkanseigyo, Circulation Control, vol. 14, No. 2, pp. 139-145, (1993).
Shinkeinaika, Neurological Medicine, vol. 50, pp. 423-428, (1999).
Terwindt et al., Neurology, vol. 50, No. 4, pp. 1105-1110, (1998).
Hatakeyama Shinji
Iimura Yoichi
Kaneda Yoshihisa
Kaneko Toshihiko
Kimura Manami
Eisai Co. Ltd.
McKenzie Thomas
LandOfFree
Piperazine compound and pharmaceutical composition... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperazine compound and pharmaceutical composition..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazine compound and pharmaceutical composition... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3470448